Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind study of tralokinumab in adults with uncontrolled severe asthma
2011-001360-21Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tralokinumab in asthma (3 arms), sponsored by AstraZeneca. Primary endpoint: Asthma exacerbation rate over 52 weeks. Started May 2011; status: completed.
02
Drugs
tralokinumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2011-001360-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001360-21.